Group 1 - JunDa Co., Ltd. announced that the comprehensive cost-effectiveness of perovskite photovoltaic technology in extreme space environments remains to be verified [2][5] - The company has invested 30 million yuan to acquire a 16.67% stake in Starwing Chip Energy, but no formal business agreement has been signed for space photovoltaic projects [2][5] - The technology shows potential advantages in lightweight, low cost, and high radiation resistance, but long-term reliability and cost-effectiveness in space are still uncertain [2][5] Group 2 - Aotewei stated that the "space photovoltaic" sector is still in the early exploration and research phase, with significant uncertainties in the industrialization process [3] - The company emphasized that product development to commercial application requires a considerable period, and the impact of related positive expectations on actual operating performance is highly uncertain [3] Group 3 - Tongyu Communications announced its participation in the A1 round financing of Beijing Blue Arrow Hongqing Technology, investing 30 million yuan for a 1.8293% stake [3] - The company will transition from direct to indirect ownership of Hongqing Technology through a partnership agreement [3] Group 4 - Huajin Technology received approval from the China Securities Regulatory Commission for the issuance of H-shares, planning to issue up to 101,573,100 shares [4] - Trina Solar announced a change in the use of remaining raised funds, reallocating 1.7 billion yuan to a new project for distributed smart photovoltaic power station construction [4][5] Group 5 - Yunnan City Investment plans to publicly transfer a 10.5% stake in Qicai Company with a base price of 293 million yuan [6] - Zijin Mining announced the completion of the second phase of the Giant Dragon Copper Mine, increasing production capacity to 350,000 tons per day [6] Group 6 - Shuaifeng Electric expects a net profit loss of 43 million to 62 million yuan in 2025, with potential delisting risk warnings for its stock [7] - Anqi Yeast plans to invest 222 million yuan in a green manufacturing project for yeast products with an annual output of 12,000 tons [7] Group 7 - Zhengzhou Coal and Electricity announced the cessation of production at the Chaohua Coal Mine due to resource depletion and safety risks, expecting a 311 million yuan impairment loss [8] - Oujing Technology announced partial production line shutdowns at its subsidiaries to reduce losses and operating costs [8] Group 8 - North Car Blue Valley plans to invest in the construction of a high-end platform model industrialization and digital upgrade project with a total investment of 1.991 billion yuan [9] - Jingzhida signed a significant contract worth 1.311 billion yuan for semiconductor testing equipment [9] Group 9 - Yanghe Co. announced a cash dividend plan for 2025-2027, committing to distribute no less than 100% of net profit each year [10] - Yanghe Co. also projected a net profit decline of 62.18% to 68.30% for 2025 due to market adjustments and increased channel inventory [10] Group 10 - Huitong Energy expects a net profit decrease of 69.51% to 75.82% for 2025, primarily due to the absence of non-recurring income from property relocation rewards [11] - Dahua Co. reported a net profit increase of 32.65% for 2025, driven by business optimization and cost control [12] Group 11 - Hangzhou Bank reported a net profit increase of 12.05% for 2025, maintaining a stable non-performing loan ratio [12] - Aotejia expects a net profit increase of 41.85% to 79.67% for 2025, supported by sales growth and cost control measures [12] Group 12 - Shenke Co. anticipates a net profit increase of 65.75% to 98.9% for 2025, benefiting from overseas strategy and revenue growth [13] - Pioneering Technology expects a net profit increase of 50.82% to 109.21% for 2025, driven by product technology iterations and market expansion [13] Group 13 - Shanchuang Technology expects a net profit increase of 81.77% to 134.78% for 2025, fueled by demand for enterprise-level storage products [14] - Anshuo Information anticipates a net profit increase of 52.44% to 98.83% for 2025, with government subsidies contributing to the growth [14] Group 14 - Zhongwei Company expects a net profit increase of 28.74% to 34.93% for 2025, driven by increased customer recognition of its plasma etching equipment [15] - Jingfang Technology anticipates a net profit increase of 44.41% to 52.32% for 2025, benefiting from the automotive industry's growth [16] Group 15 - Fuda Alloy expects a net profit increase of 119.14% to 219.95% for 2025, driven by strong demand in emerging applications [17] - Feirongda anticipates a net profit increase of 57.23% to 83.43% for 2025, supported by stable growth in communication and cooling business [17] Group 16 - Licheng Performing Arts expects a net profit decrease of 12.75% to 32.21% for 2025, impacted by regional travel environment fluctuations [22] - Lisheng Pharmaceutical anticipates a net profit increase of 116.77% to 138.44% for 2025, driven by market expansion and product sales [23] Group 17 - JMC reported a net profit decrease of 22.71% for 2025, despite a 2.07% increase in total revenue [27] - Daoshi Technology expects a net profit increase of 206.01% to 269.76% for 2025, driven by overseas business expansion [28] Group 18 - Jin Kai New Energy plans to repurchase shares worth 500 million to 600 million yuan, with a maximum repurchase price of 7.5 yuan per share [29] - Longyun Co. announced a stock suspension due to plans to acquire a 58% stake in Yuheng Film Industry [30]

力生制药表示，报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业 集团有限公司分红因素影响，归属净利润同比增幅较大。 北京商报讯（记者 丁宁）1月23日晚间，力生制药（002393）发布2025年业绩预告显示，预计2025年实 现归属净利润4亿元至4.4亿元，同比增长116.77%-138.44%。 ...

Market Performance - The three major A-share indices collectively rose on January 23, with over 3,900 stocks closing higher, including 121 stocks hitting the daily limit up [1] - For the week, the Shanghai Composite Index increased by 0.83%, the Shenzhen Component Index rose by 1.11%, while the ChiNext Index fell by 0.34% [2] Weekly Stock Performance - Over 4,200 stocks rose this week, with 35 stocks gaining over 30%. The largest increase was seen in *ST Lifan, which surged by 95.52% [3] - Other notable gainers included *ST K Pharmaceutical and Fenglong Co., which both saw increases exceeding 50% [3] - The power equipment sector had 10 stocks listed among those with over 30% gains, while the machinery and non-ferrous metals sectors had 4 stocks each [3] Top Gainers - The top gainers for the week included: - *ST Lifan: 95.52% increase, closing at 1.31 yuan [4] - *ST K Pharmaceutical: 70.37% increase, closing at 0.92 yuan [4] - Fenglong Co.: 61.08% increase, closing at 99.53 yuan [4] - Other significant gainers included companies in construction decoration and power equipment sectors [4] Weekly Decliners - Among the stocks that declined, 46 stocks fell by over 10%, with Koma Materials dropping over 30% [5] - Other notable decliners included Silin Jie and Bofei Electric, which saw declines of over 24% [5] Institutional Activity - Institutions were active in the market, with 160 stocks appearing on the institutional leaderboard, net buying 102 stocks and net selling 58 stocks [7] - The highest net buying was seen in Shengxin Lithium Energy, which rose by 26.38% with a net institutional purchase of approximately 638.55 million yuan [9] - Other stocks with significant institutional net buying included Quanfeng Technology and Hunan Silver, with net purchases of 604.81 million yuan and 352.97 million yuan, respectively [9] Notable Announcements - Shuaifeng Electric announced an expected net loss of 43 million to 62 million yuan for 2025, with projected revenue between 210 million to 250 million yuan [12] - Anqi Yeast plans to invest 222 million yuan in a new green manufacturing project for yeast products [13] - Construction Machinery expects a net loss of approximately 2.072 billion yuan for 2025, attributed to a downturn in the tower crane rental market [13] - Aerospace Electric anticipates a net loss of 39 million to 58 million yuan for 2025, impacted by industry overcapacity and competitive pressures [13] - Lisheng Pharmaceutical forecasts a net profit of 400 million to 440 million yuan for 2025, representing a year-on-year increase of 116.77% to 138.44% [14]

力生制药（002393）(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润4亿元 至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...

智通财经APP讯，力生制药(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 4亿元至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...

中证智能财讯力生制药（002393）1月23日晚间披露2025年度业绩预告，预计2025年归母净利润4亿元至4.4亿元，同比增长116.77%-138.44%；扣非净利润预 计1.6亿元至1.9亿元，同比增长55.34%-84.47%；基本每股收益1.5元/股-1.8元/股。以1月23日收盘价计算，力生制药目前市盈率（TTM）约为13.22倍-14.54 倍，市净率（LF）约1.17倍，市销率（TTM）约4.41倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况 (倍) 350 327.17 @00 250 200 150 100 50 28:07 28.55 30825 4:86 0 2020-12-37 1 2027-12-37 022-12-37 2-06-30 2n- 公司 -{○- 行业均值 100 95 58 07 ହ 90 80 70 ed 2 60 50 45.02 44616 40 30 20 10 7.63 0 2021-12-37 1 2020-12-37 ' <022-72-37 ' 5-12-37 . -06-30 2-06-30 2n- ← ...

Group 1 - The company, Lisheng Pharmaceutical, announced an expected net profit attributable to shareholders of 400 million to 440 million yuan for the fiscal year 2025, indicating a growth of 116.77% to 138.44% compared to the previous year [2]

格隆汇1月23日丨力生制药(002393.SZ)公布，预计2025年归属于上市公司股东的净利润40000万元-44000 万元，比上年同期增长116.77%-138.44%，扣除非经常性损益后的净利润16000万元-19000万元，比上年 同期增长55.34%-84.47%。 报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业集团有限公司分 红因素影响，归属于上市公司股东的净利润同比增幅较大。 ...

Core Viewpoint - Tianjin Development (00882) expects its indirect non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), to achieve a net profit attributable to shareholders of the listed company of 400 million to 440 million yuan for the fiscal year 2025, representing a significant increase of 116.77% to 138.44% compared to the previous year's profit of 185 million yuan [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 160 million to 190 million yuan, up from 103 million yuan in the previous year, indicating a growth of 55.34% to 84.47% [1] - Basic earnings per share are expected to be between 1.50 yuan and 1.80 yuan [1] Market Expansion - The company has been increasing its market expansion efforts, leading to improved product sales [1] - The significant year-on-year increase in net profit is also influenced by dividend factors from Tianjin Tasly Biological Pharmaceutical Industry Group Co., Ltd. [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：882） 海外監管公告 本公告乃天津發展控股有限公司（「本公司」）根據證券及期貨條例（香港法 例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條及 第13.10B條而作出。 本公司間接非全資附屬公司天津力生製藥股份有限公司（「力生製藥」）於深 圳證券交易所網站(www.szse.cn)刊發有關其二零二五年度業績預告之公告，該 公告之全文轉載於本公告附頁。 於本公告日期，本公司間接持有力生製藥約34.11%之已發行股本。 主席及執行董事 滕飛 香港，二零二六年一月二十三日 於本公告日期，本公司董事會包括滕飛先生、翟欣翔博士 、 夏濱輝先生 、 孫利軍先生 * 、伍綺琴女士 ** 、黃紹開先生 ** 、樓家強先生 ** 及冼漢廸先生 ** 。 * 非執行董事 ** 獨立非執行董事 证券代码：002393 证券简称：力生制药 公告编号：202 ...